| Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. | |
| | |
MedLine Citation:
|
PMID: 17023232 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients at high risk for hypertension may require several therapeutic agents to lower their blood pressure to guideline-recommended targets. Some antihypertensive agents are more effective than others in protecting against cardiovascular morbidity and mortality. Numerous beta-blocking agents have been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. Previous trials have demonstrated that although all beta-blockers effectively reduce blood pressure, there are differences in how they affect various metabolic factors. In 2 trials, a novel controlled-release (CR) formulation of carvedilol will be tested against other selective beta-blockers to determine whether differences exist in their individual effects on cardiovascular risk factors. These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors. |
| | |
Authors:
|
George L Bakris; Elizabeth A Tarka; Brian Waterhouse; Michelle R Goulding; Anuradha Madan; Karen M Anderson; Martin St John Sutton; Alan B Miller; Nathaniel Reichek |
Publication Detail:
|
Type: Journal Article Date: 2006-08-28 |
Journal Detail:
|
Title: The American journal of cardiology Volume: 98 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2006 Oct |
Date Detail:
|
Created Date: 2006-10-06 Completed Date: 2007-02-20 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 46L-52L Citation Subset: AIM; IM |
Affiliation:
|
Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA. gbakris@earthlink.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage,
adverse effects,
therapeutic use* Antihypertensive Agents / administration & dosage, therapeutic use Antilipemic Agents / adverse effects, therapeutic use Carbazoles / adverse effects, therapeutic use* Delayed-Action Preparations / adverse effects, therapeutic use* Drug Therapy, Combination Dyslipidemias / blood, complications, drug therapy* Humans Hypertension / blood, complications, drug therapy* Hypertrophy, Left Ventricular / blood, complications, drug therapy* Propanolamines / adverse effects, therapeutic use* Randomized Controlled Trials as Topic Research Design Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Antilipemic Agents; 0/Carbazoles; 0/Delayed-Action Preparations; 0/Propanolamines; 72956-09-3/carvedilol |
| Comments/Corrections | |
Erratum In:
|
Am J Cardiol. 2007 Aug 1;100(3):562 Am J Cardiol. 2007 Mar 15;99(6):878 Note: St John Sutton, Martin [added]; Miller, Alan B [added]; Reichek, Nathaniel [added] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfuncti...
Next Document: COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection f...